DexCom develops and markets medical devices called continuous glucose monitoring (CGM) systems that help people with diabetes track their blood glucose levels. In contrast, CGMs eliminate the need for fingersticks, are automatic, and continuously track patients' glucose levels, measuring them up to once every five minutes. For one, there are some half a billion adults with diabetes worldwide, only about 1% of whom have access to CGM technology. DexCom has established itself as a leader in the CGM market, despite competing with the larger Abbott Laboratories. Overall, given its rebounding financial results, long runway for growth, and innovative abilities that have allowed it to be one of the leaders in CGM technology, DexCom's prospects look attractive.